Humacyte (HUMA) to Release Earnings on Friday

Humacyte (NASDAQ:HUMA) will be issuing its quarterly earnings data before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the previous year, the company earned ($0.21) EPS. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Trading Up 1.5 %

Shares of HUMA stock opened at $4.61 on Wednesday. Humacyte has a 1-year low of $1.96 and a 1-year high of $5.60. The firm has a market cap of $548.96 million, a PE ratio of -4.31 and a beta of 1.27. The company has a 50-day moving average of $3.49 and a two-hundred day moving average of $3.11. The company has a debt-to-equity ratio of 1.20, a current ratio of 4.52 and a quick ratio of 4.52.

Analyst Ratings Changes

HUMA has been the subject of a number of research analyst reports. Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of Humacyte in a report on Tuesday, March 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research report on Monday, April 1st. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Monday, March 25th.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.